| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5526643 | European Journal of Cancer | 2017 | 9 Pages |
â¢Cost-effectiveness analyses regarding the addition of bevacizumab to taxane therapy based on real-world data was performed.â¢This is the first report on this topic using real-world data.â¢The study gives insight in the real-world cost-effectiveness of bevacizumab added to taxane chemotherapy.â¢The addition of bevacizumab is not cost-effective for HER2- negative MBC patients in daily practice in the Netherlands.
IntroductionThe aim of our analysis was to assess the real-world cost-effectiveness of bevacizumab in addition to taxane treatment versus taxane monotherapy for HER2-negative metastatic breast cancer compared with the cost-effectiveness based on the efficacy results from a trial.MethodsA state transition model was built to estimate costs, life years (LYs) and quality-adjusted life years (QALYs) for both treatments. Two scenarios were examined: a real-world scenario and a trial-based scenario in which transition probabilities were primarily based on a real-world cohort study and the E2100 trial, respectively. In both scenarios, costs and utility parameter estimates were extracted from the real-world cohort study. Moreover, the Dutch health care perspective was adopted.ResultsIn both the real-world and trial scenarios, bevacizumab-taxane is more expensive (incremental costs of â¬56,213 and â¬52,750, respectively) and more effective (incremental QALYs of 0.362 and 0.189, respectively) than taxane monotherapy. In the real-world scenario, bevacizumab-taxane compared to taxane monotherapy led to an incremental cost-effectiveness ratio (ICER) of â¬155,261 per QALY gained. In the trial scenario, the ICER amounted to â¬278,711 per QALY gained.ConclusionAccording to the Dutch informal threshold, bevacizumab in addition to taxane treatment was not considered cost-effective for HER2-negative metastatic breast cancer both in a real-world and in a trial scenario.
